EP3980069A4 - METHODS OF TREATMENT OF A SPLENOMEGALY - Google Patents

METHODS OF TREATMENT OF A SPLENOMEGALY Download PDF

Info

Publication number
EP3980069A4
EP3980069A4 EP21738476.7A EP21738476A EP3980069A4 EP 3980069 A4 EP3980069 A4 EP 3980069A4 EP 21738476 A EP21738476 A EP 21738476A EP 3980069 A4 EP3980069 A4 EP 3980069A4
Authority
EP
European Patent Office
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21738476.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3980069A1 (en
Inventor
Wayne Philip Rothbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telios Pharma Inc
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Priority to EP22150344.4A priority Critical patent/EP4000624A1/en
Publication of EP3980069A1 publication Critical patent/EP3980069A1/en
Publication of EP3980069A4 publication Critical patent/EP3980069A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP21738476.7A 2020-01-08 2021-01-08 METHODS OF TREATMENT OF A SPLENOMEGALY Pending EP3980069A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22150344.4A EP4000624A1 (en) 2020-01-08 2021-01-08 Btk inhibitors for treating splenomegaly

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP22150344.4A Division-Into EP4000624A1 (en) 2020-01-08 2021-01-08 Btk inhibitors for treating splenomegaly
EP22150344.4A Division EP4000624A1 (en) 2020-01-08 2021-01-08 Btk inhibitors for treating splenomegaly

Publications (2)

Publication Number Publication Date
EP3980069A1 EP3980069A1 (en) 2022-04-13
EP3980069A4 true EP3980069A4 (en) 2022-08-17

Family

ID=76788747

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22150344.4A Pending EP4000624A1 (en) 2020-01-08 2021-01-08 Btk inhibitors for treating splenomegaly
EP21738476.7A Pending EP3980069A4 (en) 2020-01-08 2021-01-08 METHODS OF TREATMENT OF A SPLENOMEGALY

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22150344.4A Pending EP4000624A1 (en) 2020-01-08 2021-01-08 Btk inhibitors for treating splenomegaly

Country Status (14)

Country Link
EP (2) EP4000624A1 (zh)
JP (1) JP2023509968A (zh)
KR (1) KR20220130151A (zh)
CN (1) CN114423457A (zh)
AU (1) AU2021205484A1 (zh)
BR (1) BR112022013646A2 (zh)
CA (1) CA3164063A1 (zh)
CO (1) CO2022010592A2 (zh)
CR (1) CR20220374A (zh)
IL (1) IL294582A (zh)
JO (1) JOP20220168A1 (zh)
MA (1) MA57226B1 (zh)
MX (1) MX2022008490A (zh)
WO (1) WO2021142257A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
CN114423457A (zh) * 2020-01-08 2022-04-29 泰利奥斯制药公司 治疗脾肿大的方法
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
US20160122365A1 (en) * 2014-10-03 2016-05-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
WO2021097213A1 (en) * 2019-11-14 2021-05-20 Quogue Ip Holdings Llc Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423457A (zh) * 2020-01-08 2022-04-29 泰利奥斯制药公司 治疗脾肿大的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
US20160122365A1 (en) * 2014-10-03 2016-05-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
WO2021097213A1 (en) * 2019-11-14 2021-05-20 Quogue Ip Holdings Llc Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASHANGARI CHANDRALEKHA ET AL: "Hairy Cell Leukemia Variant", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 5562, XP086591091, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-110192 *
JAMIE L DARGART ET AL: "Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 95, no. 1, 7 May 2012 (2012-05-07), pages 49 - 56, XP028491144, ISSN: 0166-3542, [retrieved on 20120516], DOI: 10.1016/J.ANTIVIRAL.2012.05.003 *
MICHAEL L. WANG ET AL: "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 6, 8 August 2013 (2013-08-08), US, pages 507 - 516, XP055484912, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1306220 *
ON BEHALF OF THE INVESTIGATORS OF THE ITALIAN REGISTRY OF MYELOFIBROSIS WITH MYELOID METAPLASIA AND THE MYELOPROLIFERATIVE DISORDE: "The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia", BLOOD CELLS, MOLECULES & DISEASES, LAJOLLA, US, vol. 38, no. 3, 4 April 2007 (2007-04-04), pages 280 - 286, XP022014560, ISSN: 1079-9796, DOI: 10.1016/J.BCMD.2007.01.003 *

Also Published As

Publication number Publication date
CA3164063A1 (en) 2021-07-15
MA57226B1 (fr) 2023-06-28
KR20220130151A (ko) 2022-09-26
MA57226A1 (fr) 2023-02-28
MX2022008490A (es) 2022-10-13
BR112022013646A2 (pt) 2022-10-04
JOP20220168A1 (ar) 2023-01-30
JP2023509968A (ja) 2023-03-10
WO2021142257A1 (en) 2021-07-15
EP4000624A1 (en) 2022-05-25
IL294582A (en) 2022-09-01
AU2021205484A1 (en) 2022-08-18
CN114423457A (zh) 2022-04-29
CO2022010592A2 (es) 2022-10-31
EP3980069A1 (en) 2022-04-13
CR20220374A (es) 2023-01-25

Similar Documents

Publication Publication Date Title
EP3980069A4 (en) METHODS OF TREATMENT OF A SPLENOMEGALY
EP4028044A4 (en) METHODS OF TREATMENT OF KRAS MUTANT CANCERS
EP3908650A4 (en) METHODS OF TREATMENT OF CANCER
EP4017493A4 (en) TREATMENT METHODS USING BCN057 AND BCN512
EP3938364A4 (en) COMPOUNDS AND METHODS OF TREATING DISEASES
EP3946345A4 (en) NEUROPATHIC PAIN TREATMENT METHODS
EP4065106A4 (en) METHOD FOR TREATING HIV-1 INFECTIONS
AU2021903030A0 (en) Methods of treatment
AU2021902512A0 (en) Methods of treatment
AU2021900789A0 (en) Methods of treatment
AU2020903332A0 (en) Methods of treatment
AU2020902585A0 (en) Methods of treatment
AU2020900580A0 (en) Methods of Treatment
AU2021900740A0 (en) Combination Methods of Treatment
AU2023902382A0 (en) Methods of treatment
AU2021903789A0 (en) Methods of treating sars-cov-2 infection
AU2021902405A0 (en) Method of treatment
AU2021900204A0 (en) Method of treatment
AU2020900433A0 (en) Method of treatment
AU2020900220A0 (en) Method of Treatment
EP4065573A4 (en) TREATMENT METHODS
EP4025218A4 (en) TREATMENT PROCESSES
EP4103200A4 (en) METHOD OF TREATMENT USING META-ARSENITE
AU2019903451A0 (en) Methods of treatment
AU2019902672A0 (en) Methods of treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: A61K0031498500

A4 Supplementary search report drawn up and despatched

Effective date: 20220714

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20220711BHEP

Ipc: A61K 31/519 20060101ALI20220711BHEP

Ipc: A61K 31/4985 20060101AFI20220711BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073175

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS